Gossamer Bio (GOSS) Operating Leases (2019 - 2026)

Gossamer Bio has reported Operating Leases for 8 years, with the latest figure at $3.9 million in Q2 2026.

• On a quarterly basis, Operating Leases fell 18.68% year-over-year to $3.9 million in Q2 2026; TTM through Jun 2026 was $3.9 million, a 18.68% decrease from a year earlier, with the FY2025 full-year figure at $3.5 million, down 21.33% from the prior year.
• Operating Leases was $3.9 million for Q2 2026 at Gossamer Bio, down from $4.2 million in the prior quarter.
• The five-year high for Operating Leases was $8.5 million in Q1 2022, with the low at $144000.0 in Q4 2023.
• Average Operating Leases over 5 years is $4.6 million, with a median of $4.5 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Operating Leases slumped 95.82% in 2023, then soared 2954.17% in 2024.
• Over 5 years, Operating Leases stood at $3.4 million in 2022, then plunged by 95.82% to $144000.0 in 2023, then jumped by 2954.17% to $4.4 million in 2024, then slipped by 21.33% to $3.5 million in 2025, then increased by 13.38% to $3.9 million in 2026.
• The last three Operating Leases figures came in at $3.9 million (Q2 2026), $4.2 million (Q1 2026), and $3.5 million (Q4 2025), per Business Quant data.